Navigation Links
Cyberonics Provides Update on Depression Post-Approval Study
Date:7/24/2009

"plan," "intend," and "forecast," or other similar words. Statements contained in this press release are based upon information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information should those facts change or should we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning completing follow-up on patients enrolled in the D-21 clinical study. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquiries and any litigation relating thereto and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refe
'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
6. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 21, 2014 Clementia ... Medicines Agency (EMA) has granted Orphan Medicinal ... product candidate, for the treatment of fibrodysplasia ... severely disabling genetic disease characterized by painful, ... and new abnormal bone formation. This process, ...
(Date:11/21/2014)... IRVINE, Calif. , Nov. 20, 2014  Edwards ... leader in the science of heart valves and hemodynamic ... corporate giving in 2014 to support a strong launch ... Heartbeat Matters , and to improve the global communities ... In 2014, Edwards, global corporate giving will exceed $8 ...
(Date:11/21/2014)... /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced today ... be presenting at the 26 th Annual Piper Jaffray ... New York . The formal presentation is scheduled ... addition, Mr. Krakauer and Jorgen B. Hansen , President ... the day. An audio webcast will be ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... of power morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive ... 450 new signatures since the end of October, Bernstein ... had signed the petition as of November 21st, 2014. ... 31st, when 86,042 supporters had signed on to the ...
(Date:11/22/2014)... wide variety and complexity of foods served at holiday ... allergies, an expert warns. "Every person is different ... that it can be really difficult to avoid all ... allergy and clinical immunology at Wake Forest Baptist Medical ... you know you have food allergies, caution should overrule ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... filed on behalf of patients who allegedly developed Type ... forward in the federal multidistrict litigation now underway in ... LLP reports. According to court documents, the litigation will ... 10:00 a.m. The Court has directed Lead Counsel for ...
(Date:11/22/2014)... Hastings and Hastings, a discount accident attorney in ... with the option of leaving an online review using ... and easy to navigate website that has recently been ... allows clients to research the Hastings and Hastings law ... when retaining an attorney. Those who have been injured ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3
... treatment for women that cuts off blood flow to ... appropriate treatment for women in a Clinical Therapeutics article ... England Journal of Medicine . "UFE (also called ... and minimally invasive option for women to consider. This ...
... , SAN FRANCISCO, Aug. 13 Nile Therapeutics, ... of novel therapeutics for heart failure patients, today announced its second quarter ... , , For the second quarter of 2009, ... share, compared to a net loss of approximately $3.8 million, or $0.16 ...
... , , DENVER, Aug. ... BDMS ) , operators of PERFECT TEETH ... and six months ended June 30, 2009. For the quarter ended ... 2.0%, to $15.2 million. Net revenue increased $93,000, or 1.1%, to ...
... areas of the brain needed to perceive feelings, study ... drinking can affect the ability to recognize other people,s ... used functional MRI to monitor brain activity in 15 ... faces with positive or negative emotional expressions. The brain ...
... , GUANGZHOU, China, Aug. 13 ... Medicine" or "the Company"), a developer,and a leading distributor ... (TCM), nutritional and dietary supplements, and,medical devices and medical ... Second Quarter 2009 Highlights:, ...
... , New England Journal of Medicine Highlights ... Decrease Hysterectomy Rate in United States , , ... invasive interventional radiology treatment for women that cuts off blood flow ... treatment for women in a Clinical Therapeutics article in the Aug. ...
Cached Medicine News:Health News:Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option 2Health News:Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option 3Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 2Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 3Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 4Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 2Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 3Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 4Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 5Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 6Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 7Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 8Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 9Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 10Health News:Boozing Blunts Ability to Read Faces 2Health News:China Medicine Announces Second Quarter 2009 Results 2Health News:China Medicine Announces Second Quarter 2009 Results 3Health News:China Medicine Announces Second Quarter 2009 Results 4Health News:China Medicine Announces Second Quarter 2009 Results 5Health News:China Medicine Announces Second Quarter 2009 Results 6Health News:China Medicine Announces Second Quarter 2009 Results 7Health News:China Medicine Announces Second Quarter 2009 Results 8Health News:China Medicine Announces Second Quarter 2009 Results 9Health News:China Medicine Announces Second Quarter 2009 Results 10Health News:China Medicine Announces Second Quarter 2009 Results 11Health News:China Medicine Announces Second Quarter 2009 Results 12Health News:China Medicine Announces Second Quarter 2009 Results 13Health News:China Medicine Announces Second Quarter 2009 Results 14Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 2Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 3Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 4Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 5
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... the best of both worlds, the ... is the latest addition to the ... bipolar cautery instruments for ophthalmic surgery. ... extrusion aspiration and backflush functionality in ...
...
...
Medicine Products: